Yayın:
Assessment of palliative care in lung cancer in Turkey

dc.contributor.buuauthorErol, Mehmet Muharrem
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Cerrahisi Ana Bilim Dalı
dc.contributor.researcheridCPM-5715-2022
dc.contributor.scopusid35605916500
dc.date.accessioned2023-09-24T13:01:20Z
dc.date.available2023-09-24T13:01:20Z
dc.date.issued2017
dc.descriptionÇalışmada 43 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.
dc.description.abstractObjective: To investigate the symptoms of lung cancer in Turkey and to evaluate approaches to alleviate these symptoms. Subjects and Methods: This study included 1,245 lung cancer patients from 26 centers in Turkey. Demographic characteristics as well as information regarding the disease and treatments were obtained from medical records and patient interviews. Symptoms were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and were graded on a scale between 0 and 10 points. Data were compared using the. 2, Student t, and Mann-Whitney U tests. Potential predictors of symptoms were analyzed using logistic regression analysis. Results: The most common symptom was tiredness (n = 1,002; 82.1%), followed by dyspnea (n = 845; 69.3%), appetite loss (n = 801; 65.7%), pain (n = 798; 65.4%), drowsiness (n = 742; 60.8%), anxiety (n = 704; 57.7%), depression (n = 623; 51.1%), and nausea (n = 557; 45.5%). Of the 1,245 patients, 590 (48.4%) had difficulty in initiating or maintaining sleep. The symptoms were more severe in stages III and IV. Logistic regression analysis indicated a clear association between demographic characteristics and symptom distress, as well as between symptom distress (except nausea) and well-being. Overall, 804 (65.4%) patients used analgesics, 630 (51.5%) received treatment for dyspnea, 242 (19.8%) used enteral/parenteral nutrition, 132 (10.8%) used appetite stimulants, and 129 (10.6%) used anxiolytics/antidepressants. Of the 799 patients who received analgesics, 173 (21.7%) reported that their symptoms were under control, and also those on other various treatment modalities (dyspnea: 78/627 [12.4%], appetite stimulant: 25/132 [18.9%], and anxiolytics/antidepressants: 25/129 [19.4%]) reported that their symptoms were controlled. Conclusion: In this study, the symptoms progressed and became more severe in the advanced stages of lung cancer, and palliative treatment was insufficient in most of the patients in Turkey.
dc.identifier.citationBülbül, Y. vd. (2017). ''Assessment of palliative care in lung cancer in Turkey''. Medical Principles and Practice, 26(1), 50-56.
dc.identifier.doi10.1159/000452801
dc.identifier.endpage56
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue1
dc.identifier.pubmed27780164
dc.identifier.scopus2-s2.0-84992688577
dc.identifier.startpage50
dc.identifier.urihttps://doi.org/10.1159/000452801
dc.identifier.urihttps://karger.com/mpp/article/26/1/50/207403/Assessment-of-Palliative-Care-in-Lung-Cancer-in
dc.identifier.urihttp://hdl.handle.net/11452/33997
dc.identifier.volume26
dc.identifier.wos000391457100008
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherKarger
dc.relation.collaborationYurt içi
dc.relation.journalMedical Principles and Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGeneral &iInternal medicine
dc.subjectLung cancer
dc.subjectPalliation
dc.subjectPalliative treatment
dc.subjectSymptoms
dc.subjectTreatment
dc.subjectQuality-of-life
dc.subjectSleep disturbances
dc.subjectSymptom experience
dc.subjectSupportive care
dc.subjectPain
dc.subjectChemotherapy
dc.subjectPrevalence
dc.subjectImpact
dc.subject.emtreeAntidepressant agent
dc.subject.emtreeAnxiolytic agent
dc.subject.emtreeAppetite stimulant
dc.subject.emtreeBisphosphonic acid derivative
dc.subject.emtreeBronchodilating agent
dc.subject.emtreeCyproheptadine
dc.subject.emtreeFentanyl
dc.subject.emtreeMegestrol acetate
dc.subject.emtreeMorphine
dc.subject.emtreeNonsteroid antiinflammatory agent
dc.subject.emtreeParacetamol
dc.subject.emtreeSedative agent
dc.subject.emtreeTramadol
dc.subject.emtreeVitamin
dc.subject.emtreeAnalgesic agent
dc.subject.emtreeAdult
dc.subject.emtreeAnalgesia
dc.subject.emtreeAnxiety disorder
dc.subject.emtreeArticle
dc.subject.emtreeBone metastasis
dc.subject.emtreeCachexia
dc.subject.emtreeCancer fatigue
dc.subject.emtreeCancer pain
dc.subject.emtreeCancer palliative therapy
dc.subject.emtreeCancer patient
dc.subject.emtreeCancer radiotherapy
dc.subject.emtreeCombination drug therapy
dc.subject.emtreeComparative study
dc.subject.emtreeControlled study
dc.subject.emtreeDepression
dc.subject.emtreeDrowsiness
dc.subject.emtreeDysphagia
dc.subject.emtreeDyspnea
dc.subject.emtreeEdmonton symptom assessment scale
dc.subject.emtreeFemale
dc.subject.emtreeHuman
dc.subject.emtreeLoss of appetite
dc.subject.emtreeLung cancer
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMiddle aged
dc.subject.emtreeNasogastric tube
dc.subject.emtreeNausea
dc.subject.emtreeNebulizer
dc.subject.emtreeNoninvasive ventilation
dc.subject.emtreeDisease severity
dc.subject.emtreeNutritional support
dc.subject.emtreeOxygen therapy
dc.subject.emtreePain severity
dc.subject.emtreeParenteral nutrition
dc.subject.emtreePercutaneous endoscopic gastrostomy
dc.subject.emtreePleurodesis
dc.subject.emtreeProspective study
dc.subject.emtreePsychopharmacotherapy
dc.subject.emtreeSleep disorder
dc.subject.emtreeStent
dc.subject.emtreeSymptom assessment
dc.subject.emtreeThoracocentesis
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeVitamin supplementation
dc.subject.emtreeWellbeing
dc.subject.emtreeAged
dc.subject.emtreeCancer staging
dc.subject.emtreeComplication
dc.subject.emtreeDyspnea
dc.subject.emtreeFatigue
dc.subject.emtreeInterview
dc.subject.emtreeLung neoplasms
dc.subject.emtreePain
dc.subject.emtreePalliative therapy
dc.subject.emtreePsychology
dc.subject.emtreeQuality of life
dc.subject.emtreeSquamous cell carcinoma
dc.subject.emtreeStatistical model
dc.subject.emtreeTurkey
dc.subject.emtreeComorbidity
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAnalgesics
dc.subject.meshComorbidity
dc.subject.meshDyspnea
dc.subject.meshFatigue
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInterviews as topic
dc.subject.meshLogistic models
dc.subject.meshLung neoplasms
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshNeoplasm staging
dc.subject.meshNeoplasms
dc.subject.meshSquamous cell
dc.subject.meshPain
dc.subject.meshPalliative care
dc.subject.meshQuality of Life
dc.subject.meshTurkey
dc.subject.scopusChildhood Cancer Survivor; Sleep Disorders; Breast Neoplasms
dc.subject.wosMedicine, general & internal
dc.titleAssessment of palliative care in lung cancer in Turkey
dc.typeArticle
dc.wos.quartileQ2
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göğüs Cerrahisi Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Erol_vd_2017.pdf
Boyut:
158.03 KB
Format:
Adobe Portable Document Format
Açıklama

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama